HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a leader in pharmaceutical-grade cannabis manufacturing, is pleased to announce it has entered into strategic supply agreements (the “Agreements”) and successfully completed vendor qualification with two cannabis cultivators under its Good Manufacturing Practice (GMP) system qualifying a minimum of 4000 kg of cannabis for the German market.

This milestone builds on HYTN’s recent announcements outlining its strategic transition into international pharmaceutical sales, including partnerships with SNDL Inc (SNDL) and 4C Labs, and further strengthens its manufacturing scope, positioning the Company for continued global expansion.

The Agreements, which were entered into in February 2025, were subject to HYTN’s rigorous qualification process through which the Company conducted comprehensive site audits, quality control evaluations, and verified compliance with Good Agricultural and Collection Practices (GACP) to ensure alignment with German pharmacopoeia standards.

These Agreements establish strict product specifications, testing protocols, and pricing structures, ensuring compliance with stringent microbiological limits and non-irradiation requirements while securing a reliable and consistent cannabis supply for Germany. The two cultivators which have been qualified in HYTN’s system for the German market are Klonetics Plant Science Inc. and another Kelowna company which has requested non-disclosure.

With qualification complete, the approved cultivators will commence production, focusing on high-potency cultivars specifically tailored for German patient needs HYTN’s GMP-certification ensures that all cannabis destined for Germany will adhere to the highest pharmaceutical standards, meeting the country’s exacting regulatory requirements.

“With global demand for GMP-certified cannabis increasing, HYTN remains committed to partnering with the most qualified cultivators to ensure seamless integration into international medical markets,” said Jason Broome, HYTN Chief Operating Officer. He added, “We are proud to support patient access to premium medical cannabis in Germany and look forward to establishing HYTN as a preferred partner for pharmaceutical-grade cannabis in Europe.”

Germany’s medical cannabis sector is experiencing rapid growth, driven by increasing patient adoption, expanded physician prescribing, and broadening pharmacy distribution. In Q3 2024 alone, Germany imported 20,000 kilograms of medical cannabis. This was more than double the quarterly average prior to the April 2024 regulatory reforms and demonstrated surging demand for compliant pharmaceutical cannabis products¹.

HYTN anticipates the arrival of the initial cultivation batches for GMP processing in Q2 2025, with the first shipments to Germany expected in late Q2 2025.